CCL20 is a Potential Therapeutic Target Associated with Immune Infiltration in Breast Cancer

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2023 Aug 12

PMID 37571985

Authors

Hongyan Zhai

Na Zhang

Dan Mo

Tingting Qin

Affiliations

Soon will be listed here.

Abstract

Objectives: CCL20 is a chemotactic factor that is involved in immune cell recruitment and cancer progression. However, the role of CCL20 in the prognosis of breast cancer remains unclear. This study analyzed correlations between CCL20 expression and immune infiltration, clinicopathological parameters, and prognosis in breast cancer patients.

Methods: Correlations between CCL20 expression and clinicopathological parameters, prognosis, and immune infiltration in breast cancer were determined using the TIMER, UALCAN, and PrognoScan databases. Furthermore, gene-gene and protein-protein interactions were determined using GeneMANIA and STING network construction, respectively.

Results: CCL20 expression was significantly upregulated in breast cancer and had significant associations with clinicopathological features, including race, sex, age, menopause status, cancer stage, cancer subclass, and nodal metastasis; moreover, patients with higher CCL20 expression exhibited poor prognosis. Meanwhile, CCL20 expression was significantly correlated with the infiltration of immune cells in breast cancer, including monocytes, neutrophils, tumor-associated macrophages, Th1 cells, regulatory T cells, and exhausted T cells. Moreover, the network of CCL20 expression showed the majority genes and proteins were associated with immune reactions.

Conclusions: CCL20 is a prognosis-related biomarker in breast cancer on the basis of its correlation with immune infiltration levels and has potential to also be a therapeutic target.

Citing Articles

Immune dynamics throughout life in relation to sex hormones and perspectives gained from gender-affirming hormone therapy.

Yalcinkaya A, Yalcinkaya R, Sardh F, Landegren N Front Immunol. 2025; 15:1501364.

PMID: 39885993 PMC: 11779622. DOI: 10.3389/fimmu.2024.1501364.

New Strategies for Macrophage Re-Education in Cancer: An Update.

Lampiasi N Int J Mol Sci. 2024; 25(6).

PMID: 38542388 PMC: 10970142. DOI: 10.3390/ijms25063414.

References

Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X . D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872783. DOI: 10.1073/pnas.2114851119. View

Liu Y, Lagowski J, Gao S, Raymond J, White C, Kulesz-Martin M . Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. J Invest Dermatol. 2010; 130(5):1384-90. PMC: 2898505. DOI: 10.1038/jid.2009.416. View

Muscella A, Vetrugno C, Marsigliante S . CCL20 promotes migration and invasiveness of human cancerous breast epithelial cells in primary culture. Mol Carcinog. 2017; 56(11):2461-2473. DOI: 10.1002/mc.22693. View

Kitamura T, Pollard J . Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol Res. 2015; 100:266-70. PMC: 4617477. DOI: 10.1016/j.phrs.2015.08.004. View

Shen M, Smith H, Wei Y, Jiang Y, Zhao S, Wang N . Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nat Cancer. 2022; 3(1):60-74. PMC: 8818088. DOI: 10.1038/s43018-021-00280-y. View

Pack C, Bommireddy R, Munoz L, Patel J, Bozeman E, Dey P . Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer. Hum Vaccin Immunother. 2020; 16(12):3184-3193. PMC: 8641616. DOI: 10.1080/21645515.2020.1754691. View

Kim T, Jee H, Fuentes-Duculan J, Wu W, Byamba D, Kim D . Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis. J Invest Dermatol. 2014; 134(5):1462-1465. DOI: 10.1038/jid.2013.534. View

Boyle S, Faulkner J, McColl S, Kochetkova M . The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages. Mol Cancer. 2015; 14:115. PMC: 4464622. DOI: 10.1186/s12943-015-0394-1. View

Lee S, Park K, Kim H, Park J, Son S, Kim K . Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. Sci Rep. 2017; 7(1):9610. PMC: 5575024. DOI: 10.1038/s41598-017-09040-4. View

10.

Hieshima K, Imai T, Opdenakker G, Van Damme J, Kusuda J, Tei H . Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem. 1997; 272(9):5846-53. DOI: 10.1074/jbc.272.9.5846. View

11.

Armas-Gonzalez E, Dominguez-Luis M, Diaz-Martin A, Arce-Franco M, Castro-Hernandez J, Danelon G . Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis. Arthritis Res Ther. 2018; 20(1):114. PMC: 5992813. DOI: 10.1186/s13075-018-1611-2. View

12.

Lyu M, Li Y, Hao Y, Lyu C, Huang Y, Sun B . CCR6 defines a subset of activated memory T cells of Th17 potential in immune thrombocytopenia. Clin Exp Immunol. 2018; 195(3):345-357. PMC: 6378379. DOI: 10.1111/cei.13233. View

13.

Nandi B, Pai C, Huang Q, Prabhala R, Munshi N, Gold J . CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis. PLoS One. 2014; 9(5):e97566. PMC: 4035256. DOI: 10.1371/journal.pone.0097566. View

14.

Marsigliante S, Vetrugno C, Muscella A . Paracrine CCL20 loop induces epithelial-mesenchymal transition in breast epithelial cells. Mol Carcinog. 2015; 55(7):1175-86. DOI: 10.1002/mc.22360. View

15.

Wang D, Yang L, Yu W, Wu Q, Lian J, Li F . Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling. J Immunother Cancer. 2019; 7(1):215. PMC: 6688336. DOI: 10.1186/s40425-019-0701-2. View

16.

Maruthanila V, Elancheran R, Kunnumakkara A, Kabilan S, Kotoky J . Recent development of targeted approaches for the treatment of breast cancer. Breast Cancer. 2016; 24(2):191-219. DOI: 10.1007/s12282-016-0732-1. View

17.

Chen W, Qin Y, Wang D, Zhou L, Liu Y, Chen S . CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018; 16(7):e2005869. PMC: 6082578. DOI: 10.1371/journal.pbio.2005869. View

18.

Skovdahl H, Damas J, Granlund A, Ostvik A, Doseth B, Bruland T . C-C Motif Ligand 20 (CCL20) and C-C Motif Chemokine Receptor 6 (CCR6) in Human Peripheral Blood Mononuclear Cells: Dysregulated in Ulcerative Colitis and a Potential Role for CCL20 in IL-1β Release. Int J Mol Sci. 2018; 19(10). PMC: 6214005. DOI: 10.3390/ijms19103257. View

19.

Kapur N, Mir H, Clark Iii C, Krishnamurti U, Beech D, Lillard J . CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer. 2016; 114(12):1343-51. PMC: 4984452. DOI: 10.1038/bjc.2016.113. View

20.

Schutyser E, Struyf S, Van Damme J . The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003; 14(5):409-26. DOI: 10.1016/s1359-6101(03)00049-2. View